D9078C00001 (PACIFIC-9): A Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy

Objective

Closed to enrollment effective 30June2025

Clinical Trial Details

Clinical Trial Categories

• Lung Cancer

Contact

Medical Oncology Research Coordinators at 605-322-3295
or medoncresearch@avera.org